Two new alliacane sesquiterpenes from the fruiting bodies of edible mushroom Gomphus purpuraceus

He, Yi; Wan, Yanyu; Zhou, Yiqing; Xiao-rong, Cai; Guo, Zhiyong; Hu, Feifei; Ye, Qin; Deng, Zhangshuang

doi:10.1016/j.phytol.2022.06.002

Cited by 3 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Owing to the outstanding flavor and old health myths, some researchers have begun to focus on the extraction and functional assessment of the bioactive compounds in G. purpuraceus . Thus far, only two alliacane sesquiterpenes were found in the fruiting bodies of G. purpuraceus [ 11 , 12 ]. According to previous reports, terpenoids have some health-promoting properties, such as protecting the liver, detoxification, decreasing blood pressure, lowering blood fat and other medicinal functions [ 13 , 14 , 15 ].…”

Section: Introductionmentioning

confidence: 99%

Whole-Genome Sequencing and Comparative Genomics Analysis of the Wild Edible Mushroom (Gomphus purpuraceus) Provide Insights into Its Potential Food Application and Artificial Domestication

Geng

Zhang

Yang

et al. 2022

Genes

View full text Add to dashboard Cite

Gomphus purpuraceus (Iwade) Yokoyama is a species of wild fungi that grows in southwest China, considered an edible and medicinal fungus with potential commercial prospects. However, the detailed mechanisms related to the development of mycelium and the formation of the fruiting body are unclear. To obtain a comprehensive overview of genetic features, whole-genome and comparative genomics analyses of G. purpuraceus were performed. High-quality DNA was extracted from the mycelium, which was isolated from a fresh fruiting body of G. purpuraceus. The DNA sample was subjected to sequencing using Illumina and Oxford Nanopore sequencing platforms. A genome assembly totaling 40.15 Mb in 50 contigs with an N50 length of 2.06 Mb was generated, and 8705 putative predicted genes were found. Subsequently, phylogenetic analysis revealed a close evolutionary relationship between G. purpuraceus and Gomphus bonarii. Moreover, a total of 403 carbohydrate-active enzymes (CAZymes) were identified in G. purpuraceus, which included 147 glycoside hydrolases (GHs), 85 glycosyl transferases (GTs), 8 polysaccharide lyases (PLs), 76 carbohydrate esterases (CEs), 57 auxiliary activities (AAs) and 30 carbohydrate-binding modules (CBMs). Compared with the other 13 fungi (Laccaria bicolor, Russula virescens, Boletus edulis, etc.), the number and distribution of CAZymes in G. purpuraceus were similar to other mycorrhizal fungi. Furthermore, the optimization of culture medium for G. purpuraceus showed the efficient utilization of disaccharides such as sucrose and maltose. The genome of G. purpuraceus provides new insights into its niche, food applications and potential artificial domestication.

show abstract

Section: Introductionmentioning

confidence: 99%

Whole-Genome Sequencing and Comparative Genomics Analysis of the Wild Edible Mushroom (Gomphus purpuraceus) Provide Insights into Its Potential Food Application and Artificial Domestication

Geng

Zhang

Yang

et al. 2022

Genes

View full text Add to dashboard Cite

show abstract

“…: Fr.) Earle (formerly named Marasmius alliaceus ), featuring an epoxidized hydrindane structure with a butyrolactone moiety, was the first reports of alliacane-type sesquiterpenoids. − Further examples for secondary metabolites possessing an alliacane skeleton are the group of clitocybulols, isolated from Clitocybula oculus (clitocybulols A–C) and Pleurotus cystidiosus (clitocybulols D–O), , the purpuracolides A–C from Gomphus purpuraceus , , incarnetic acid from Gloeostereum incarnatum , and the inonoalliacanes A–I from Inonotus sp., which are to some degree structurally related to nebucanes E–G ( 5 – 7 ). Notably, these fungi belong to various different families and orders in the Agaricomycetes, and it is presently not possible to draw any conclusions on potential chemotaxonomic correlations.…”

Section: Resultsmentioning

confidence: 99%

Alliacane-Type Secondary Metabolites from Submerged Cultures of the Basidiomycete Clitocybe nebularis

et al. 2022

View full text Add to dashboard Cite

Seven sesquiterpenoids, named nebucanes A–G (1–7), featuring a rare alliacane scaffold with unprecedented furan or pyrrole functions, were isolated from the fermentation broth of Clitocybe nebularis. Their structures were established on the basis of 1D/2D NMR spectroscopic analyses, HR-(+)-ESIMS spectra, and comparison of measured and calculated CD spectra for determination of the absolute configuration. Assessing the biological activities, nebucane D (4) exhibited antifungal effects against Rhodotorula glutinis, while nebucane G (7) displayed significant cytotoxicity against MCF-7 and A431 cell lines.

show abstract

“…For example, alliacane sesquiterpenes–purpuracolide B and purpuracolide C extracted from edible fungus Gomphus purpuraceus (Iwade) K. Yokoy. 1989 are inactive against MDA-MB-231 cell line ( He et al, 2022 ). This shows how time-consuming and tedious it can be to work on the selection, extraction and testing of a metabolite that may have cytotoxic properties against cancer cells.…”

Section: Secondary Metabolites As Anticancer Agentsmentioning

confidence: 99%

The therapeutic potential of natural metabolites in targeting endocrine-independent HER-2-negative breast cancer

Püsküllüoğlu,

Michalak

2024

Front. Pharmacol.

View full text Add to dashboard Cite

Breast cancer (BC) is a heterogenous disease, with prognosis and treatment options depending on Estrogen, Progesterone receptor, and Human Epidermal Growth Factor Receptor-2 (HER-2) status. HER-2 negative, endocrine-independent BC presents a significant clinical challenge with limited treatment options. To date, promising strategies like immune checkpoint inhibitors have not yielded breakthroughs in patient prognosis. Despite being considered archaic, agents derived from natural sources, mainly plants, remain backbone of current treatment. In this context, we critically analyze novel naturally-derived drug candidates, elucidate their intricate mechanisms of action, and evaluate their pre-clinical in vitro and in vivo activity in endocrine-independent HER-2 negative BC. Since pre-clinical research success often does not directly correlate with drug approval, we focus on ongoing clinical trials to uncover current trends. Finally, we demonstrate the potential of combining cutting-edge technologies, such as antibody-drug conjugates or nanomedicine, with naturally-derived agents, offering new opportunities that utilize both traditional cytotoxic agents and new metabolites.

show abstract

Two new alliacane sesquiterpenes from the fruiting bodies of edible mushroom Gomphus purpuraceus

Cited by 3 publications

References 7 publications

Whole-Genome Sequencing and Comparative Genomics Analysis of the Wild Edible Mushroom (Gomphus purpuraceus) Provide Insights into Its Potential Food Application and Artificial Domestication

Whole-Genome Sequencing and Comparative Genomics Analysis of the Wild Edible Mushroom (Gomphus purpuraceus) Provide Insights into Its Potential Food Application and Artificial Domestication

Alliacane-Type Secondary Metabolites from Submerged Cultures of the Basidiomycete Clitocybe nebularis

The therapeutic potential of natural metabolites in targeting endocrine-independent HER-2-negative breast cancer

Contact Info

Product

Resources

About